Current Report Filing (8-k)
October 11 2019 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): October 7, 2019
NeuroOne
Medical Technologies Corporation
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-54716
|
|
27-0863354
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
10901
Red Circle Dr., Suite 150, Minnetonka, MN 55343
(Address
of principal executive offices and zip code)
952-426-1383
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On October 7, 2019, NeuroOne
Medical Technologies Corporation (the “Company”) entered into a lease agreement (the “Lease”)
with Biynah Cleveland, LLC, BIP Cleveland, LLC, and Edenvale Investors (together, the “Landlord”) pursuant
to which the Company has agreed to lease office space located at 7599 Anagram Drive, Eden Prairie, Minnesota (the “Premises”).
The Company anticipates taking possession of the Premises on November 1, 2019, with the term of the Lease ending 65 months after
such date, unless terminated earlier (the “Term”).
The
initial base rent for the Premises is $6,410.25 per month for the first 17 months, increasing to $47,075.72 per month by the end
of the Term, and adjustable in accordance with the terms of the lease. In addition, as long as the Company is not in default under
the Lease Agreement, the Company shall be entitled to an abatement of its base rent for the first 3 months. In addition, the Company
will pay its pro rata share of the Landlord’s annual operating expenses associated with the premises, calculated as set
forth in the Lease. The Lease contains customary provisions allowing Landlord to terminate the Lease if the Company fails to remedy
a breach of any of its obligations within specified time periods.
The
foregoing description of the Lease is only a summary and is qualified in its entirety by reference to the complete terms and conditions
of the Lease, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
October 11, 2019
|
NEUROONE
MEDICAL TECHNOLOGIES CORPORATION
|
|
|
|
|
By:
|
/s/
David Rosa
|
|
|
David
Rosa
|
|
|
Chief
Executive Officer
|
2